Consistently, blocking B7-H4 in breast cancer is synergistic with PD-1 blockage [30], trastuzumab treatment [31], and doxorubicin, paclitaxel, and carboplatin [29], suggesting it is widely involved in resistance to anti-cancer therapies. This evidence concerns the gene VTCN1 and breast cancer.